AbbVie Inc.

What they do

AbbVie operates as a single global business segment focused on the research, development, manufacturing, and commercialization of innovative medicines. Its product portfolio includes immunology products (Skyrizi, Rinvoq, Humira), neuroscience products (Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev), oncology products (Venclexta, Imbruvica, Elahere), and aesthetics products (Botox Cosmetic, Juvederm). The company operates globally, with commercial efforts organized by geography and therapeutic area.

Revenue drivers

• Immunology portfolio — Includes Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor) for autoimmune diseases; Q2 2026 global net revenues of $8.786 billion, up 15.1% reported, driven by Skyrizi at $5.505 billion (up 24.4%) and Rinvoq at $2.525 billion (up 24.5%).
• Neuroscience portfolio — Includes Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, and Vyalev; Q2 2026 global net revenues of $3.228 billion, up 20.3% reported, with Vraylar at $1.071 billion (up 18.9%).
• Oncology portfolio — Includes Venclexta, Imbruvica, and Elahere; Q2 2026 global net revenues of $1.650 billion, down 1.5% reported, with Venclexta at $771 million (up 11.6%) and Imbruvica at $532 million (declining).
• Aesthetics portfolio — Includes Botox Cosmetic and Juvederm; Q2 2026 global net revenues of $1.282 billion, up 0.3% reported (down 0.9% operational), with Botox Cosmetic at $728 million.

Recent performance

For Q2 2026, AbbVie reported net revenues of $16.990 billion, up 10.2% reported (9.5% operational) from prior year. GAAP diluted EPS was $2.03, up 290.4%, while adjusted diluted EPS was $3.65, up 22.9%. Operating earnings were $6.432 billion for the quarter. For the six months, net revenues were $31.992 billion and net earnings attributable to AbbVie were $4.308 billion.

Strategy

AbbVie is focused on advancing its pipeline and strengthening its immunology leadership. In Q2 2026, the company announced a definitive agreement to acquire Apogee Therapeutics, which is expected to close in Q3 2026. Management emphasizes execution and pipeline advancement as key to long-term shareholder value creation. The company continues to expand indications for Skyrizi and Rinvoq across multiple autoimmune conditions.

Risks

• Patent expirations and biosimilar competition — Loss of exclusivity for products like Humira (Q2 2026 revenues down 35.9%) could reduce revenues if biosimilar competition intensifies.
• Regulatory and approval risks — Delays or failures in clinical trials or regulatory approvals for pipeline products or new indications could impact growth expectations.
• Acquisition integration risks — The proposed Apogee Therapeutics acquisition may not close as anticipated or may fail to deliver expected synergies, affecting financial performance.
• Market competition — Intense competition from other pharmaceutical companies in immunology, neuroscience, oncology, and aesthetics could pressure market share and pricing.

Outlook

AbbVie updated its 2026 adjusted diluted EPS guidance range from $13.91-$14.11 to $13.87-$14.07, including an unfavorable $0.14 per share dilutive impact from the Apogee acquisition and $0.58 per share from acquired IPR&D and milestones expense incurred through Q2. Management remains confident in the long-term outlook based on substantial momentum in the business. The Apogee acquisition is expected to close in Q3 2026.